BXCL501
BXCL501-303
Phase 3 small_molecule completed
Quick answer
BXCL501 for Agitation is a Phase 3 program (small_molecule) at BioXcel Therapeutics with 4 ClinicalTrials.gov record(s).
Program details
- Company
- BioXcel Therapeutics
- Indication
- Agitation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed